BioCentury
ARTICLE | Company News

Emerging company roundup: Kintai, Nocion, Arrakis and more

April 19, 2019 11:01 PM UTC

In a busy week for Boston-area biotechs, at least two companies debuted -- microbiome-mimicking small molecule company Kintai and pain play Nocion -- while a third, Arrakis, raised a $75 million series B round.

Kintai Therapeutics Inc. (Cambridge, Mass.), Flagship Pioneering’s latest foray into microbiome-based medicines, emerged from stealth mode Tuesday to develop oral small molecules that mimic microbes’ therapeutic effects. The company, whose financing is not disclosed, is led by CEO Paul-Peter Tak (see “Kintai’s Host-targeting Niche in Flagship Microbiome Ecosystem”). ...